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Phosphorylation of the RSRSP 
stretch is critical for splicing 
regulation by RNA-Binding Motif 
Protein 20 (RBM20) through 
nuclear localization
Rie Murayama1, Mariko Kimura-Asami1,2, Marina Togo-Ohno1,2, Yumiko Yamasaki-Kato1,3, 
Taeko K. Naruse3,4, Takeshi Yamamoto5, Takeharu Hayashi3,4, Tomohiko Ai4,6, Katherine G. 
Spoonamore6, Richard J. Kovacs6, Matteo Vatta7, Mai Iizuka1, Masumi Saito1, Shotaro Wani1, 
Yuichi Hiraoka8,9, Akinori Kimura3,4 & Hidehito Kuroyanagi1,2,3,10
RBM20 is a major regulator of heart-specific alternative pre-mRNA splicing of TTN encoding a 
giant sarcomeric protein titin. Mutation in RBM20 is linked to autosomal-dominant familial dilated 
cardiomyopathy (DCM), yet most of the RBM20 missense mutations in familial and sporadic cases were 
mapped to an RSRSP stretch in an arginine/serine-rich region of which function remains unknown. 
In the present study, we identified an R634W missense mutation within the stretch and a G1031X 
nonsense mutation in cohorts of DCM patients. We demonstrate that the two serine residues in 
the RSRSP stretch are constitutively phosphorylated and mutations in the stretch disturb nuclear 
localization of RBM20. Rbm20S637A knock-in mouse mimicking an S635A mutation reported in a familial 
case showed a remarkable effect on titin isoform expression like in a patient carrying the mutation. 
These results revealed the function of the RSRSP stretch as a critical part of a nuclear localization signal 
and offer the Rbm20S637A mouse as a good model for in vivo study.
Dilated cardiomyopathy (DCM) is a heart disease characterized by left ventricular dilatation and systolic dys-
function1,2. Within a group idiopathic DCM, 30-50% are familial, with autosomal dominant inheritance in most 
cases2,3. Today, next-generation sequencing methods have identified over 400 potentially causative mutations in 
nearly 60 genes of various functional groups including muscle contraction, Ca2+ handling and nuclear functions 
both in familial and sporadic DCM cases4. Such complexity in molecular genetics of DCM, however, makes it 
challenging to elucidate mechanisms eventually leading to the common phenotypes of DCM1.
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RBM20, encoding RNA binding motif protein 20 (RBM20), was identified as one of the genes linked to 
autosomal-dominant familial DCM5. RBM20 has later been identified as an alternative splicing regulator of a 
gene responsible for expression of an aberrantly giant isoform of a sarcomeric protein titin in a spontaneously 
occurring rat strain6. Titin is the largest known protein and the gene for titin, TTN, has the largest number of 
exons (363 in humans) in vertebrates7–9. One titin molecule spans from the Z-disk through the M-band of a sarco-
mere, a contractile unit of striated muscles, and functions as a molecular spring contributing to passive tension of 
cardiomyocytes10–12. In adult hearts, two major titin isoforms are expressed: N2B is a shorter isoform where exon 
50 is spliced to exon 219 and exons in between are all skipped; N2BA is a mixture of multiple intermediate iso-
forms where exons 102–108 encoding N2A-specific element and some of variable exons 51 through 100 encoding 
immunoglobulin (Ig) repeats are included13. In an Rbm20 mutant rat strain lacking nearly all of the Rbm20 exons, 
titin N2B is no longer expressed and N2BA is predominant in the heterozygotes, and an aberrantly giant isoform 
N2BA-G, in which all of the exons 51–218 are included, is exclusively expressed in the homozygotes, indicating 
that RBM20 is a key regulator of Ttn pre-mRNA processing in the adult heart6. Since titin-based passive tension 
is negatively correlated with its molecular size10,12,14, the ratio of the isoforms and the amount of the titin proteins 
are considered to impact passive stiffness of the myocardium and progression of DCM15–17.
RBM20 protein consists of multiple evolutionarily conserved domains including one RNA-recognition motif 
(RRM) domain and two zinc finger (ZnF) domains6, and directly binds to its target pre-mRNAs in cardiomyo-
cytes18. Nevertheless, extensive search for mutations in RBM20 in familial and sporadic DCM patients revealed 
a hotspot of missense mutations at a highly conserved RSRSP stretch within an arginine/serine (RS)-rich region 
and not in the putative RNA-binding domains5,6,19–22. Some missense and nonsense mutations outside of the 
hotspot were also identified in such screenings19,20,23,24, yet neither family study nor functional study was per-
formed and significance of such mutations remains to be elucidated. This situation is unusual considering that 
most of missense mutations were mapped to the RRM domains in our previous genetic screenings for loss- or 
reduction-of-function mutants for splicing factors25–27. It therefore remains to be unraveled why any residue in 
the RSRSP stretch is critical for the function of RBM20 and to what extent the mutations outside of the stretch 
affect the function.
In this study, we identified one missense mutation R634W in the RSRSP stretch and one truncation muta-
tion G1031X losing one of the ZnF domains in RBM20 in DCM patients. We utilized a fluorescence splicing 
reporter to evaluate the function of RBM20 and demonstrate that phosphorylation of the RSRSP stretch is crit-
ical for nuclear localization of the splicing regulator. We also investigated functional alterations caused by the 
DCM-associated RBM20 mutations including three other missense variants that were reported to be found in 
other DCM patients.
Materials and Methods
Identification of RBM20 mutations in DCM patients. RBM20 from DCM patients were screened for 
mutations in exons and exon-intron boundaries by using next-generation sequencing or by Sanger sequencing 
with di-deoxy chain termination method and automated nucleotide sequencers. Identified mutations were con-
firmed by Sanger sequencing in the proband patients and their family relatives by Sanger sequencing. Sequences 
of primers used in this study will be published elsewhere and are available upon request. Written informed con-
sent for genetic analysis was obtained from patients when the patients were 16 years of age or older and/or from 
legal guardians such as their parents when the patients were under 16 years of age, as well as from family members 
who were 16 years of age or older. Unaffected family members under 16 years of age were not included in the 
genetic testing study. All research was performed in accordance with the guidelines for human genome analysis in 
Japan and USA, and the study protocol was approved by the Ethics Committee of the Medical Research Institute, 
Tokyo Medical and Dental University (TMDU) and that of the Indiana University School of Medicine.
In silico prediction of RBM20 missense mutations. In silico analysis of missense variants was per-
formed using Polyphen-2, SIFT, Mutation Taster, PROVEAN and FATHMM28–32. The variants were classified 
“Damaging” if they were determined to be “probably damaging” or “possibly damaging” in Polyphen-2, “damag-
ing” in SIFT, “deleterious” in PROVEAN, “damaging” in FATHMM or “disease causing” in Mutation Taster. The 
variants were also evaluated by ClinVar database33. The variants were classified in accordance with the American 
College of Medical Genetics and Genomics (ACMG) Standards and Guidelines34.
Plasmid construction. The Ttn splicing reporter minigene was constructed by using Gateway technology 
(Invitrogen) as follows. Genomic DNA fragments of Ttn spanning from exon 50 through exon 51 and from exon 
218 through exon 219 were amplified by using PrimeSTAR GXL DNA Polymerase (Takara) and cloned into 
Gateway pENTR-L1/R5 vector (Invitrogen). A human histone H2B fragment was amplified from HeLa genomic 
DNA and cloned into a pDEST-cDNA3 vector backbone25 by using In-Fusion HD (Takara), and a cryptic splice 
site was mutagenized for constructing pDEST-cDNA3-H2B(RMver). EGFP cDNA with a 6x (Gly-Gly-Ser) 
linker35, porcine teschovirus-1 2 A fragment and mCherry cDNA (Clontech) were assembled in Gateway 
pENTR-L5/L2 vector (Invitrogen). Finally, the TtnE50-E51E218-E219-EGFP/mCherry minigene was constructed 
by assembling the Entry vectors and pDEST-cDNA3-H2B(RMver) with LR clonase II Plus (Invitrogen). The 
primers used to amplify the DNA fragments are available in Supplementary Table 1.
A full-length RBM20 cDNA was amplified from mouse heart cDNAs by using PrimeSTAR GXL (Takara) 
and cloned into pENTR/D-TOPO (Invitrogen). Entry vectors for RBM20 point mutants and deletion mutants 
were constructed by using PCR-based techniques with PrimeSTAR GXL (Takara). Expression vectors for 
N-terminally FLAG-tagged wild-type and mutant RBM20 proteins were generated by homologous recombina-
tion between pDEST-cDNA3-FLAG or pDEST-cDNA3-FLAG-3xNLS and the Entry vectors with LR clonase II 
(Invitrogen). pDEST-cDNA3-FLAG was constructed by converting pcDNA3-FLAG into a Destination vector36 
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and pDEST-cDNA3-FLAG-3xNLS was constructed by inserting three copies of SV40 nuclear localization signals 
(NLSs) into pDEST-cDNA3-FLAG. Wild-type and mutant RBM20(517–657) cDNA fragments were amplified 
from RBM20 expression vectors and cloned into a pcDNA3-FLAG vector backbone with In-Fusion HD (Takara). 
Sequences of primers used in the construction are listed in Supplementary Table 1 and sequence information of 
all the vectors is available upon request.
Cell culture and transfection. HeLa and HEK293T cells were cultured in DMEM Medium (Nacalai) sup-
plemented with 10% fetal bovine serum at 37 °C with 5% CO2. Plasmid DNAs were transfected by using FuGENE 
HD (Promega) according to the manufacturer’s instruction. The Ttn reporter minigene and the expression vec-
tors for FLAG-tagged wild-type or mutant RBM20 proteins were co-transfected in a 1:4 mixture. Fluorescence 
images of fluorescent proteins were acquired 24–36 hours after transfection by using Leica system, and then, the 
cells were harvested for total RNA preparation and RT-PCR analysis
Immunofluorescence staining and microphotography. HeLa cells transfected with FLAG-tagged 
RBM20 expression vectors were fixed with 1–4% paraformaldehyde in PBS for 10 min. The cells were permeabi-
lized with PBS containing 0.1% Triton X-100 and 2% normal goat serum for 30 min and were stained with 2 µg/ml 
anti-FLAG monoclonal antibody (M2, Sigma-Aldrich) for 1 hour, 2 µg/ml Alexa546-conjugated goat anti-mouse 
IgG (Molecular Probes) for 30 min and DAPI (Invitrogen). Fluorescence images were captured by using a com-
pound microscope (DM6000B, Leica) equipped with a color, cooled CCD camera (DFC310FX, Leica) and pro-
cessed by using LAS AF (Leica) and Photoshop CC (Adobe).
Total RNA extraction and RT-PCR. Total RNAs from HeLa and HEK293T cells were extracted by using 
Sepasol-RNA I Super G (Nacalai), treated with RQ1 RNase-free DNase (Promega) and reverse transcribed with 
PrimeScript II and oligo dT (Takara). Total RNAs from mouse heart were extracted by using RNeasy Plus Mini 
kit with DNase I (Qiagen) and reverse transcribed with PrimeScript II, random hexamers and oligo dT (Takara). 
Semi-quantitative PCRs were performed by using PrimeStarGXL or ExTaq (Takara) and the PCR products were 
analyzed by utilizing Bioanalyzer 2100 Expert with DNA1000 or DNA7500 Kit (Agilent). Sequences of the PCR 
primers used are available in Supplementary Table 2. Sequences of the PCR products were confirmed by direct 
sequencing or by cloning and sequencing. Statistical significance was assessed by one-way ANOVA followed by 
Dunnett’s post-hoc test versus RBM20WT or Tukey-Kramer test by using R.
Immunoprecipitation and phosphatase treatment. HEK293T cells expressing FLAG-tagged RBM20 
proteins were lysed either with 5:1 mixture of RIPA buffer (Thermo) and 5 M NaCl (Nacalai) on ice or with SDS 
sample buffer at 95 °C. The lysates were sonicated in a water bath (UCD-300, Cosmo Bio), and the FLAG-RBM20 
proteins were immuno-precipitated with anti-FLAG M2 Magnetic Beads (Sigma).
For calf intestine alkaline phosphatase (CiAP, Takara) treatment, the FLAG-RBM20 proteins on the magnetic 
beads were incubated with the enzyme in CiAP buffer at 37 °C for 90 min. For λ protein phosphatase (λPP, NEB) 
treatment, the beads were incubated in λPP buffer at 30 °C for 90 min. Heat-inactivation of the phosphatases were 
performed by pre-incubating the enzyme mixture at 65 °C for 1 hour. The FLAG-RBM20 proteins on the beads 
were then denatured with SDS or LDS sample buffer.
Electrophoresis and staining of proteins. FLAG-tagged RBM20 proteins expressed in HEK293T cells or 
immuno-precipitated and subsequently treated with CiAP and λPP were separated by neutral polyacrylamide gel 
electrophoresis (NuPAGE, Invitrogen). The NuPAGE gel was stained with Pro-Q Diamond (Molecular Probes) 
according to the manufacturer’s instruction, and fluorescence images were acquired with FluoroPhore Star3000 
(Anatech). The gel was then stained with Gel-Negative Staining Kit (Nacalai). For Phos-tag SDS-PAGE, a 15% 
polyacrylamide gel without or with 25 µM Phos-tag (Wako) and 50 µM MnCl2 was prepared and layered with a 
standard 4.5% stacking gel according to the manufacturer’s instruction. Protein samples were run with standard 
SDS running buffer (Nacalai). Vertical SDS-agarose gel electrophoresis of cardiac proteins from mice were per-
formed essentially as described previously37. The proteins were detected by staining with CBB (Bio Craft). The 
images of the stained gels were captured with a scanner GT-X700 (Epson) and processed by using Photoshop CC 
(Adobe).
Anti-phospho-RBM20 antibody. Rabbit polyclonal anti-phospho-RBM20 antiserum was raised with 
a synthetic phospho-peptide CYGPERPR(pS)R(pS)(Amd) by MBL, Nagoya, Japan. The serum was absorbed 
with a non-phospho-peptide CYGPERPRSRS(Amd) to yield TF1049–02 and further absorbed four times with a 
phospho-peptide CR(pS)R(pS)R(pS)R(pS) to yield TF1510-A.
Western blot analysis. Proteins separated by standard SDS-PAGE, Phos-tag SDS-PAGE or NuPAGE were 
transferred to nitrocellulose membrane (Protran BA85, Whatman). The membranes were blocked with 5% skim 
milk and then incubated with 1 µg/ml anti-phospho-RBM20 (TF1049-02 or TF1510-A), anti-DDDDK-tag pol-
yclonal antibody (MBL) or anti-FLAG monoclonal antibody (M2, Sigma) and 1:1,000-diluted HRP-conjugated 
anti-rabbit IgG antibody (Amersham or Pierce) or anti-mouse IgG antibody (MBL). Chemiluminescence signals 
(West Dura, Thermo) were detected by using LAS4000 (GE Healthcare).
Knock-in mouse. Rbm20S637A knock-in mice were generated by utilizing cloning-free CRISPR/Cas system 
as described previously38. The sequences of the crRNA and tracrRNA are 5′-CUCAUUGGACUUCGAGAA 
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CGGUUUUAGAGCUAUGCUGUUUUG-3′ and 5′-AAACAGCAUAGCAAGUUAAAAUAAGGCUA 
GUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCU-3′, respectively, where an Rbm20- 
specific sequence is underlined. The sequence of the oligo DNA donor for Rbm20S637A knock-in is 5′-TG 
CAGGT TACGAGCTCTGCAGAGTCTAAACCCTGTCTCT TCCCT TCCTCCCAGGTATGGTC 
C AG AG C G G C C AC G T G C T C G A AG T C C A AT G AG C C G AT C AC T C T C C C C A AG AT C C C AT 
AGTCCCCCAGGCCCCTCTCGGGCTGACTGGGGC-3′. The oligo RNAs and the DNA donor were 
chemically synthesized and purified by high pressure liquid chromatography (FASMAC, Japan). All care and 
experimental procedures of animals were in accordance with the guidelines for the Care and Use of Laboratory 
Animals published by National Research Council (The National Academy Presses, eighth edition, 2011) and 
subjected to a prior approval by the Institutional Animal Care and Use Committee of TMDU (Approval 
#A2017-080C).
Data availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding authors on reasonable request.
Results
Identification of RBM20 mutations in DCM patients. We searched cohorts of 43 and 50 unrelated 
DCM patients for RBM20 mutations and identified two (2.2%) mutations R634W and G1031X in Japan and USA, 
respectively (Table 1). The patient with heterozygous p.Arg634Trp (R634W) mutation: 18-years-old Japanese 
male patient with DCM. His affected father, and not unaffected mother, carried the same R634W mutation in 
a heterozygous state. The patient with homozygous p.Gly1031ter (G1031X) mutation: 21-years-old African 
American male patient with seizures, aborted sudden cardiac death (SCD) associated with prolonged QTc inter-
val and severely reduced left ventricular (LV) function, compatible with the diagnosis of DCM, more specifically 
left ventricular non-compaction (LVNC). His parents did not show any cardiac symptoms, but his mother carried 
the G1031X mutation in a heterozygous state without any echocardiographic abnormalities (Table 1). A detailed 
genome analysis suggested a uniparental origin of the G1031X mutation in the patient. Detailed phenotypes 
of the patients will be reported elsewhere. Although these mutations were reported previously in other DCM 
patients19,20, their relevance to DCM remains unknown.
The R634W mutation was registered as a single nucleotide polymorphism (ID no. rs796734066) in the dbSNP 
database39, but it was not found in a nucleotide sequence database from general populations, 1000 genomes40, 
exome aggregation consortium41 or human genetic variation database42. The R634W mutation was predicted to 
cause functional alteration by using in silico prediction programs: disease-causing by Mutation Taster, probably 
damaging (score 1.000) by PolyPhen-2, damaging (score 0) by SIFT, deleterious (score −3.8) by PROVEAN, 
and damaging (score −3.37) by FATHMM. Although the R634W mutation was noted to be conflicting in the 
ClinVar database33, the R634W and G1031X were classified as likely pathogenic and pathogenic, respectively, by 
the ACMG criteria34.
Dichromatic fluorescence alternative splicing reporter for Ttn to monitor regulation activity 
of RBM20. In order to evaluate the activity of RBM20 as a critical pre-mRNA splicing regulator for pro-
ducing titin N2B isoform, we intended to construct a dichromatic Ttn alternative splicing (AS) reporter mini-
gene. Among many AS events in the Ttn pre-mRNA processing, we focused on two critical introns, intron 50 
and intron 218, both of which must not be excised during production of the titin N2B mRNA. The minigene 
TtnE50-E51E218-E219-EGFP/mCherry (Fig. 1A) carries two genomic fragments spanning from exon 50 (E50) 
through exon 51 (E51) and from exon 218 (E218) through exon 219 (E219), and the fragments are connected so 















(mm) %FS %EF Other remarks
CM701 Arg634Trp 18 yo, male 18 yo DCM 24 yo  (34 yo)* + III 76 (88)* 69 (70)* NA (10)* NA (10)* 9 (20)* 16 (35)
Proband, SCD 
at the age of 34
CM702 Arg634Trp 43 yo, male 43 yo DCM 43 yo + III 76 65 9 9 14 25–30 Father of CM701





QTc = 557 ms
MG13 Gly1031Ter 57 yo, female N/A Hyperlipidemia 57 yo − I 43 21 14 13 51 63.2 Mother of MG15
Table 1. Clinical characteristics of individuals carrying RBM20 mutations. Abbreviations. yo, years-old; DCM, 
dilated cardiomyopathy; LVNC, left ventricular non-compaction; FH, family history of cardiomyopathy and/
or sudden cardiac death; NYHA, classification of New York Heart Association; LVDd, diastolic left ventricular 
dimension; LVDs, systolic left ventricular dimension; IVST, intraventricular septum thickness; PWT, posterior 
wall thickness; %FS, % fractional shortening; %EF, % ejection fraction; SCD, sudden cardiac death; AF, atrial 
fibrillation; QTc, corrected QT interval in electrocardiogram; NA, not available. *Data at the age of 34 are in 
parentheses.
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that E51 and E218 are fused to form a 590-nt chimeric exon (E51E218). The Ttn fragments were cloned upstream 
of an EGFP/mCherry cassette where a frameshift was introduced between green (EGFP) and red (mCherry) fluo-
rescent protein cDNAs43,44. The two fluorescent proteins are produced in a mutually exclusive manner upon alter-
native splicing of the chimeric exon E51E218 (Fig. 1A); EGFP is expressed when the chimeric exon is included, 
while mCherry is expressed by N2B-type splicing where E50 is directly connected to E219.
To examine whether the TtnE50-E51E218-E219-EGFP/mCherry reporter recapitulates RBM20-dependent 
N2B-type spicing, we co-transfected the reporter minigene with an empty vector or an expression vector for 
a full-length mouse RBM20, and analyzed splicing patterns of minigene-derived mRNAs by semi-quantitative 
reverse transcription (RT)-polymerase chain reaction (PCR). Fluorescence of both EGFP and mCherry was 
detected in cells co-transfected with the empty vector (Fig. 1B, vector) and expression of the two expected 
mRNAs were confirmed (Fig. 1C, lane 1). Co-expression of wild-type RBM20 promoted expression of 
ΔE51E218-mCherry and repressed expression of E51E218-EGFP (Fig. 1B, WT and Fig. 1C, lane 2), consistent 
with its activity to promote N2B-type splicing. When conserved serine residues in the RSRSP stretch (Ser637 
and/or Ser639, corresponding to Ser635 and Ser637, respectively, in human RBM20) were replaced with ala-
nine, the splicing regulation activity was significantly affected (Fig. 1B,C, lanes 3–5). These results indicated that 
the TtnE50-E51E218-E219-EGFP/mCherry reporter could recapitulate RBM20-mediated regulation of the Ttn 
pre-mRNA processing and could be utilized to validate functional alterations caused by mutations in the RBM20 
protein.
Figure 1. Dichromatic fluorescence alternative splicing reporter for Ttn to monitor the RBM20 activity in 
splicing regulation. (A) Schematic representation of the Ttn reporter minigene TtnE50-E51E218-E219-EGFP/
mCherry (top) and mRNAs derived from it (bottom). Two genomic fragments Ttn E50-E51 and E218-E219 
were inserted between human histone H2B cDNA and the EGFP/mCherry cassette. Expression of E51E218-
EGFP and ΔE51E218-mCherry indicates inclusion and skipping of a chimeric exon E51E218, respectively.  
(B) Microphotographs of HeLa cells co-transfected with the fluorescence Ttn splicing reporter minigene and an 
empty vector or an expression vector for the wild-type (WT) or mutant RBM20 protein. Fluorescence of EGFP 
and mCherry is pseudo-colored in green and magenta, respectively. Scale bar, 100 µm. (C) RT-PCR analysis 
of the Ttn splicing reporter minigene co-expressed with an empty vector or an expression vector for the wild-
type (WT) or mutant RBM20 protein in HeLa cells. Representative gel-like presentation (left) and calculated 
inclusion levels (right) are indicated. Error bars indicate standard errors of the means. #p < 0.001 and **p < 0.01 
to WT (n = 3 biological replicates, one-way ANOVA followed by Dunnett’s test).
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The RRM domain and the zinc finger domains of RBM20 are dispensable for splicing regulation 
of the reporter. Because RBM20 protein consists of multiple domains (Fig. 2A), we next asked which 
domain(s) is/are critical for the N2B-type splicing of Ttn. To this end, we constructed expression vectors for 
RBM20 mutants in which each domain was deleted. Co-expression with the fluorescence Ttn splicing reporter 
revealed that a glutamate (E)-rich region was required for the efficient splicing regulation, whereas putative 
RNA-binding domains, an RRM domain and two ZnF domains, were dispensable for the splicing regulation 
(Fig. 2B). Semi-quantitative RT-PCR analysis confirmed the observation (Fig. 2C). To further assess requirement 
of these domains, we constructed ZnF1/ZnF2 double and ZnF1/RRM/ZnF2 triple deletion mutants and found 
that these mutants repressed the Ttn reporter exon as effectively as the wild type or the single mutants (Fig. 2D). 
Figure 2. The RRM domain and the zinc finger domains of RBM20 are not critical for splicing regulation of 
the Ttn reporter. (A) Domain structure of mouse RBM20 protein. Names and positions of the domains are 
indicated. These domains are deleted in the mutants used in panels (B–D). (B) Microphotographs of HeLa cells 
co-transfected with the fluorescence Ttn splicing reporter minigene and an expression vector for the wild-type 
(WT) or deletion mutant RBM20 protein. The images are presented as in Fig. 1B. (C,D) RT-PCR analysis of 
the Ttn splicing reporter minigene co-expressed with an expression vector for the wild-type (WT) or mutant 
RBM20 protein in HeLa cells. The data are presented as in Fig. 1C.
www.nature.com/scientificreports/
7SCIENTIfIC REPORTS |  (2018) 8:8970  | DOI:10.1038/s41598-018-26624-w
Figure 3. The RSRSP stretch is critical for nuclear localization of and not splicing regulation by RBM20. 
(A) Amino acid sequence alignment of the RS-rich region of RBM20 proteins from human (Accession 
No. NP_001127835), mouse (NP_001164318), rat (NP_001101081), chicken (XP_015144459) and frog 
(XP_002942947) by Clustal W and manual adjustment. Amino acid residues that match the human RBM20 
residues are shaded. The RSRSP stretch is boxed. Asterisks indicate evolutionarily conserved arginine (R), serine 
(S) and proline (P) residues. A line above the alignment indicates the sequence of a phospho-peptide used for 
raising anti-phospho-RBM20 antibody. (B) Immunofluorescence staining of FLAG-tagged wild-type RBM20 and 
substitution mutants RBM20S637A, RBM20S639A and RBM20S637A/S639A ectopically expressed in HeLa cells. DAPI 
staining of the same field is indicated below each panel. Scale bar, 20 µm. (C) Immunofluorescence staining of 
FLAG-tagged wild-type RBM20, RBM20S637A/S639A and RBM20S637A/S639A with three tandem copies of SV40 NLSs 
(NLS-RBM20S637A/S639A) in HeLa cells. The images are shown as in (B). (D) RT-PCR analysis of the Ttn splicing 
reporter minigene co-expressed with an expression vector for wild-type (WT) RBM20, RBM20S637A/S639A and  
NLS-RBM20S637A/S639A in HEK293T cells. The data are presented as in Fig. 1C. Significance of differences in the 
mean inclusion levels was analyzed as indicated by one-way ANOVA followed by Tukey-Kramer test.
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These data indicated that the putative RNA-binding domains were dispensable at least for the N2B-type splicing 
of the Ttn splicing reporter minigene and highlighted an essential role for the RSRSP stretch.
The RSRSP stretch is critical for nuclear localization of and not for splicing regulation by RBM20. 
In order to reveal the role for the RSRSP stretch within the RS-rich region (Figs 2A and 3A) in the splicing regu-
lation by RBM20, we analyzed effects of mutations in the stretch on subcellular localization of RBM20, because 
arginine/serine-rich (RS) domains of SR proteins, a well-characterized family of splicing factors, are known to 
play roles in their nuclear localization45,46. Wild-type (WT) RBM20 ectopically expressed in HeLa cells were local-
ized in nuclei in most cells (Fig. 3B), consistent with its function as a pre-mRNA splicing regulator. Strikingly, 
the substitution mutants RBM20S637A, RBM20S639A and RBM20S637A/S639A were excluded from the nuclei (Fig. 3B), 
indicating that these residues are essential for the nuclear localization.
Figure 4. RBM20 is constitutively phosphorylated on the RSRSP stretch and some other site(s). (A) Pro-Q 
Diamond staining (left) and negative staining (right) of immuno-precipitated and polyacrylamide gel-
electrophoresed FLAG-tagged RBM20WT and RBM20S637A/S639A expressed in HEK293T cells. The precipitated 
proteins were sequentially incubated with heat-inactivated (−) or active (+) calf intestine protein phosphatase 
(CiAP) and lambda protein phosphatase (λPP). (B) Western blot detection of immuno-precipitated FLAG-tagged 
wild-type RBM20(517–657), RBM20(517–657)S637A, RBM20(517–657)S639A and RBM20(517–657)S637A/S639A 
expressed in HEK293T cells. The proteins were separated by either standard SDS-PAGE (left) or SDS-PAGE with 
25 µM Phos-tag (right) following incubation without (−) or with (+) λPP. (C) Western blot detection of immuno-
precipitated FLAG-tagged full-length RBM20 and RBM20S637A/S639A expressed in HEK293T cells following 
incubation without (−) or with (+) λPP. Antibodies used are indicated on the right.
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To ask whether the RSRSP stretch is required only for the nuclear localization or is involved in the splicing 
regulation as well, we forced to localized the RBM20S637A/S639A mutant protein by adding nuclear localization sig-
nals (NLSs). We confirmed nuclear localization of NLS-RBM20S637A/S639A (Fig. 3C) and the splicing regulation of 
the Ttn reporter minigene was restored (Fig. 3D). These results indicated that the RSRSP stretch was critical for 
nuclear localization of and not splicing regulation by RBM20.
RBM20 is constitutively phosphorylated on the RSRSP stretch and some other residue(s). 
Given the similar functional properties of the arginine/serine-rich regions in RBM20 and the SR proteins, we 
hypothesized that the RSRSP stretch of RBM20 was phosphorylated for nuclear localization like the RS domains 
of the SR proteins45,47,48. We therefore purified RBM20WT and RBM20S637A/S639A ectopically expressed in HEK293T 
cells and stained phosphoproteins with Pro-Q Diamond after polyacrylamide gel electrophoresis. Both RBM20WT 
and RBM20S637A/S639A were stained to apparently the same extent (Fig. 4A, lanes 1 and 3), and the signals were 
completely lost by pre-incubation with active phosphatases (Fig. 4A, lanes 2 and 4). These results indicated that 
RBM20 was indeed a phosphoprotein and was phosphorylated on residue(s) outside the RSRSP stretch.
We then focused on the RS-rich region to identify the phosphorylated residues by utilizing expression vectors 
for RBM20(517–657) possessing only the RRM domain and the RS-rich region. Wild-type and mutant versions 
of the truncated RBM20 protein were immuno-precipitated, incubated without or with lambda phosphatase 
(λPP), and separated by standard or phosphate-affinity SDS-PAGE49. Under a standard SDS-PAGE condition, 
all the truncated proteins migrated to a similar extent, although the untreated proteins were slightly retarded 
Figure 5. Rbm20S637A knock-in mice are defective in producing the N2B isoform of titin in the heart. (A) 
Sequence analysis of Rbm20 mRNAs from hearts of a wild-type mouse (Wt) and a heterozygote (Het) and a 
homozygote (Homo) of Rbm20S637A knock-ins. (B) Vertical SDS-agarose gel electrophoresis and CBB staining 
of cardiac proteins from the hearts of 7-week-old Rbm20S637A knock-in mice in one litter. Genotypes of the 
individual mice are indicated above. Titin isoforms (N2B, N2BA and N2BA-G) and myosin heavy chain (MHC) 
are indicated. (C) RT-PCR analysis of Ttn mRNAs in the mice shown in (B) with E50 forward, E51 reverse 
and E219 reverse primers (top), E50 forward, E215 forward and E219 reverse primers (middle) and E115 
forward, E215 forward and E219 reverse primers (bottom). Splicing patterns of the PCR products and names 
of corresponding titin isoforms are indicated on the right. (D) RT-PCR analysis of Ldb3 (top) and Camk2d 
(bottom) mRNAs as shown in (C).
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(Fig. 4B, lanes 1–8). In the presence of 25 µM Phos-tag, mobility of the wild-type RBM20(517–657) was largely 
retarded (lane 9), indicating that RBM20(517–657)WT was constitutively phosphorylated. Substitution mutations 
at positions of Ser637 and/or Ser639 decreased the mobility shift by Phos-tag (lanes 10–12), indicating that these 
mutations diminished phosphorylation levels. λPP treatment of the wild-type and the mutant RBM20(517–657) 
proteins further increased the mobility of all these proteins to the same level equivalent to those in the stand-
ard conditions (lanes 5–8 and 13–16), indicating that the mutant proteins were still phosphorylated on other 
residue(s).
To confirm phosphorylation of the Ser637 and Ser639 residues in the RSRSP stretch, we raised 
phosphorylation-specific polyclonal antibodies against a peptide sequence fully conserved in mammals 
(Fig. 3A). The anti-phospho-RBM20 antibody detected full-length wild-type RBM20 and not RBM20S637AS639A in 
a λPP-sensitive manner (Fig. 4C). Taken together, our results demonstrate that RBM20 was highly and constitu-
tively phosphorylated on multiple residues including the two serine residues in the RSRSP stretch.
Rbm20S637A knock-in mice are defective in generating the N2B isoform of titin in the heart. To 
confirm functional reduction of RBM20 by mutations in the RSRSP stretch, we generated Rbm20S637A knock-in 
mice (Fig. 5A) by using a cloning-free CRISPR/Cas system38. We first analyzed titin isoform expression in the 
hearts from heterozygous and homozygous Rbm20S637A mice as well as a littermate control mouse. As expected, 
the cardiac titin proteins from the heterozygote migrated more slowly than those from the wild type; those from 
the homozygotes migrated further slowly (Fig. 5B). We then analyzed the splicing patterns of the endogenous 
Ttn mRNAs (Fig. 5C). The N2B isoform (as demonstrated by E50/E219 splicing) predominated over the N2BA 
isoforms (E50/E51 splicing) in the wild type, whereas the N2BA-type splicing predominated in the heterozygote 
and the N2B isoform was undetectable in the homozygotes (Fig. 5C, top panel). The isoform expressed in the 
homozygote was considered to be giant N2BA (N2BA-G)6,50 because it included exons 215–218 that were skipped 
in the wild type and even in the heterozygote (Fig. 5C, middle panel). Among the N2BA isoforms, two short 
isoforms (E115/E116/E117/E124/E219 and E115/E116/E124/E219 splicing) were predominant in the wild type 
and not in the heterozygote (Fig. 5C, bottom panel), suggesting that longer N2BA isoforms were produced in the 
heterozygote. These results were consistent with a report on a rat model of Rbm20 gene deletion6 and a mouse 
model of Rbm20ΔRRM lacking the RRM domain51. Alternative splicing of two other known target genes Ldb3 and 
Camk2d6,51 were also affected in the knock-in mice (Fig. 5D), indicating that the single amino acid substitution in 
the RSRSP stretch eliminated the function of RBM20 and dramatically affected isoform expression of the cardiac 
titin even in the heterozygous state.
Evaluation of functional alterations caused by RBM20 mutations identified in DCM patients. 
With the tools we developed in this study, we evaluated the functional relevance of mutations in the coding region of 
RBM20 we found and/or reported in DCM patients19. The RBM20 mutations analyzed in this study are summarized 
in Fig. 6A. We introduced point mutations at the corresponding positions in the mouse RBM20 expression vector 
and analyzed the effects of the mutations on splicing regulation of the Ttn splicing reporter (Fig. 6B), phosphoryla-
tion status of the RSRSP stretch (Fig. 6C), and subcellular localization of RBM20 (Fig. 6D).
Not surprisingly, R636W substitution (equivalent to R634W in human), affecting the first arginine residue 
in the RSRSP stretch, diminished splicing regulation activity of RBM20 as did the S637A substitution (Fig. 6B). 
The RBM20R636W protein was almost undetectable with the anti-phospho-RBM20 antibody (Fig. 6C) and was 
excluded from the nuclei (Fig. 6D), consistent with the idea that phosphorylation of the RSRSP stretch is neces-
sary for nuclear localization of RBM20. The other tested substitutions, D868N, P1059R and E1178K, which were 
equivalent to D888N, P1081R and E1206K in human mutations, respectively, had less effect on RBM20 properties 
at least under our experimental conditions (Fig. 6B,D). A truncation mutation G1009X (equivalent to G1031X in 
human) changed the splicing of the Ttn reporter slightly more effectively than wild-type RBM20 (Fig. 6B,D) like 
a deletion mutant lacking the second ZnF domain (Fig. 2C,D).
Discussion
In the present study, we screened panels of DCM patients and identified two known RBM20 mutations, R634W and 
G1031X, in Japanese and African American patients, respectively. To assess the functional relevance of RBM20 muta-
tions and biological role of functional domains of RBM20, we developed a fluorescence Ttn splicing reporter assay, 
and demonstrated that the two serine residues in the RSRSP stretch of RBM20 were constitutively phosphorylated and 
served as a critical part of NLS. Hence, mutations in any residue in the RSRSP stretch, a hotspot of DCM mutations, 
lead to mislocalization of RBM20 and may result in dysregulation of alternative splicing of the TTN gene and other 
target genes. On the other hand, G1031X showed an enhanced splicing activity in the Ttn mini-gene system.
As demonstrated here and in the literature, RBM20 is a crucial splicing regulator in the adult heart; even 
heterozygous mutations greatly affect titin isoform expression and cause clinical symptoms5,6,51. Paradoxically, 
the embryonic heart and skeletal muscles express long isoforms of titin, fetal N2BA and N2A, respectively, which 
include many or all of exons 51–21852–54 even though RBM20 is expressed55,56. The ratio of the titin isoforms 
varies not only during development14,52,53,56,57, but also among different muscles54, from species to species58,59, due 
to artificial volume overload to the left ventricle16 and genetic manipulation of Ttn60; all of these are dependent 
on RBM20. Such flexible regulation of RBM20-mediated alternative splicing were explained by (i) other factors 
co-acting with and/or antagonizing RBM2055,61 and (ii) signal transduction or conditions leading to changes in 
the amount of RBM20 at a transcript18 or protein62,63 level. Our present study provides insights into another layer 
of RBM20 regulation; i.e. reversible subcellular localization of RBM20 by a phosphorylation-dephosphorylation 
cycle. It is therefore intriguing to analyze phosphorylation status of endogenous RBM20 in developing heart as 
well as to monitor shuttling into and out of the nucleus in a future study.
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The R634W mutation we and others found in DCM patients (R636W in mouse), affecting the first arginine 
residue in the RSRSP stretch, diminished the function of RBM20 to an extent similar to that of the S635A muta-
tion (S637A in mouse) in our splicing reporter assay (Fig. 6). We found that these mutant RBM20 proteins were 
excluded from the nucleus (Figs 3 and 6), consistent with a previous quantitative proteomic analysis showing 
that S635A mutation in human RBM20 significantly reduced interaction with 38 splicing-related proteins18. Fatal 
effects of these mutations as well as other DCM-related mutations in the hotspot of RBM20 is likely due to loss 
of recognition of the RSRSP stretch by protein kinase(s) that phosphorylate the serine residues or by a partner 
protein that specifically binds to RBM20 only after phosphorylation of the RSRSP stretch. Loss of the second 
ZnF domain by the G1031X mutation we and others identified in DCM patients (G1009X in mouse) (Fig. 6) 
or by targeted deletion (Fig. 2) unexpectedly enhanced the repressor activity of RBM20 at least in our reporter 
assay. This may be due to destabilization or sequestration activity of the second ZnF domain and may depend on 
specific conditions of the assay such as reporter structure and/or cell types used. Either way, loss of the second 
ZnF domain affected certain aspects of the RBM20 functions. The DCM patient we reported here was apparently 
Figure 6. Evaluation of RBM20 mutations identified in DCM patients. (A) Point mutations in the coding 
region of the human RBM20 gene analyzed in this study. Domain structure of the human RBM20 protein and 
positions of the mutations are indicated. Numbers in parentheses indicate positions of corresponding residues 
in the mouse RBM20 protein. (B) RT-PCR analysis of the Ttn splicing reporter minigene co-expressed with 
an expression vector for the wild-type (WT) or mutant RBM20 protein in HeLa cells. The data are presented 
as in Fig. 1C. (C) Western blot analysis of FLAG-tagged wild-type and mutant RBM20 proteins ectopically 
expressed in HEK293T cells with anti-phospho-RBM20 (top) and anti-FLAG (bottom) antibodies. (D) 
Immunofluorescence staining of FLAG-tagged wild-type and mutant RBM20 proteins ectopically expressed in 
HeLa cells. DAPI staining of the same field is indicated below each panel. Scale bar, 20 µm.
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homozygous for the G1031X mutation, while his unaffected mother was heterozygous, indicating that the effect 
of this mutation, unlike the other familial mutations, is recessive if any. It is interesting to examine whether the 
enhanced splicing would be applicable to other target genes reported to be regulated by RBM20 in the heart6,18, 
but we could not obtain heart biopsy samples from the carrier of G1031X, because biopsy was denied by them. 
Therefore, this issue should be investigated by using, for example, cardiac cell lines homozygously knocked-in the 
G1031X mutation in the future study.
The other DCM-related missense mutations we analyzed in this study, D888N, P1081R and E1206K (D868N, 
P1059R and E1178K in mouse Rbm20, respectively)19, only moderately affected the function of RBM20 (Fig. 6). 
The differences in the effects of these potentially pathogenic mutations on RBM20 functions might explain dif-
ferences in clinical symptoms among the DCM patients although further family study or animal models are 
necessary to obtain genetic evidence. It should be noted here that D888N variant was found in ExAc database 
at 0.284%, registered in dbSNP database as rs796734066, listed as ‘conflicting’ in ClinVar database. Its in silico 
prediction data were disease-causing (Mutation Taster), probably damaging (PolyPhen-2 score 0.954), damaging 
(SIFT score 0.001), neutral (PROVEAN score −1.92) and damaging (fathmm score −2.84). On the other hand, 
P1081R and E1206K variants were found at less than 0.01%, not registered in dbSNP or ClinVar database, while 
their in silico prediction data showed both were polymorphisms (Mutation Taster) and neutral (PROVEAN). 
In addition, P1081R was predicted to be benign (PolyPhen-1 score 0.183) and tolerated (fathmm score −0.86), 
whereas E1206K was predicted to be possibly damaging (PolyPhen-2 score 0.829), damaging (SIFT score 0.001) 
and damaging (fathmm score −3.12). Therefore, the pathological significance of these variants remain to be 
further clarified.
A recent study reported a family with DCM that has a heterozygous missense mutation in the E-rich region 
(RBM20E913K/+)64. This is consistent with our finding that the E-rich region was the only domain whose deletion 
diminished the RBM20 functions (Fig. 2). An in-frame deletion of the RRM domain in mouse models resulted in 
similarly severe splicing defects as in the Rbm20 deletion rat model51, whereas deletion of the RRM domain had 
minimal effect in our reporter assay (Fig. 2). This may be explained by two distinct functions for RBM20 impli-
cated by careful analysis of RT-PCR products in the Rbm20 deletion rat strain and tethering of RBM20 in reporter 
assays55: (i) to locally bind to RBM20-repressed regions and ii) to mediate aggregation of such RBM20 proteins 
to fully repress clusters of exons. Indeed, crosslinking and immunoprecipitation coupled with high-throughput 
RNA sequencing (CLIP-seq) analysis revealed that RBM20 directly bound to UCUU-containing elements in 
flanking introns of its target exons in living cells18, yet it was not demonstrated which domains were directly 
involved in the specific recognition of the elements. The RRM domain may play critical roles in aggregating mul-
tiple RBM20 proteins to effectively repress multiple exons as in the Ttn, Ldb3 and Camk2d pre-mRNAs and not 
in repressing a single exon as in our reporter assay.
This study has demonstrated for the first time that RBM20 is phosphorylated in cells and that its phospho-
rylation on the RS-rich region is critical for its nuclear localization. A previous study on subcellular localization 
of RBM20 revealed that the RRM domain and the RS-rich region were required for nuclear retention65, yet did 
not identify a critical residue. We demonstrated that either of the two serine residues in the RSRSP stretch was 
critical. Our data in Fig. 4B suggests order of phosphorylation; Ser637 phosphorylation depends on Ser639 as the 
mobility shift of RBM20(517–657)S639A in the Phos-tag gel was equivalent to that of RBM20(517–657)S637A/S639A, 
whereas Ser639 could be phosphorylated in the S637A mutant as the mobility shift of RBM20(517–657)S637A was 
in between those of RBM20(517–657)WT and RBM20(517–657)S637A/S639A. Other residues outside of the RSRSP 
stretch were phosphorylated even in the absence of Ser637 and Ser639 (Fig. 4A,B), emphasizing that simultane-
ous phosphorylation of both of the serine residues is critical for the nuclear localization.
The amino acid composition and function of the RS-rich region of RBM20 are similar to those of the RS 
domains of the SR-family splicing factors46,66–68 in that they i) are rich in RS, SR and serine-proline (SP) dipep-
tides (Fig. 3A), (ii) reside C-terminally to RRM domain(s) (Figs 2A and 6A), (iii) are extensively phosphoryl-
ated in cells (Fig. 4), and iv) serve as NLSs (Fig. 3). Substantial differences, however, are also evident: the SR 
proteins bind to exonic elements and promote splicing in general, whereas RBM20 binds to intronic elements 
and mainly represses splicing18; the number of the RS dipeptides in the only consecutive RS repeats, constituting 
the RSRSP stretch, is only two in RBM20 (Fig. 3A), whereas the SR proteins have multiple longer RS repeats. 
Phosphorylation of the RS domains facilitate protein-protein interaction and is required for splicing45,69, whereas 
the RSRSP stretch of RBM20 appears to be required only for nuclear localization (Fig. 3). Our study implies that 
phosphorylation and likely dephosphorylation of the RSRSP stretch is the site of reversible regulation of RBM20 
activity in the heart. It is therefore interesting to identify a protein kinase and an importin protein for RBM20 in 
vivo, which will elucidate physiological and pathological relevance of the phosphorylation of RBM20.
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